Understanding Vyvanse: Cost, Composition, and Considerations for ADHD Treatment in Australia

How Much is a Vyvanse Prescription in Australia?

In Australia, the cost of a Vyvanse prescription can vary significantly based on the mechanism of payment. Under the Australian Pharmaceutical Benefits Scheme (PBS) as of 2026, general patients are required to pay a co-payment amount of approximately $25 for Vyvanse prescriptions. For those holding a concession card, the cost is lower, set at $7.70. It is essential to note that private prescriptions, which are not subsidized by the PBS, can be substantially more expensive, with prices often exceeding $200, leading to a financial burden for many families seeking treatment options for ADHD.

What is Vyvanse in Australia?

Vyvanse, known medically as lisdexamfetamine dimesilate, is a prominent medication used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and binge eating disorder. Lisdexamfetamine operates as a prodrug stimulant, meaning it requires metabolic conversion to become active. Once processed by the body, it effectively increases the concentration of certain neurotransmitters in the brain, particularly dopamine and norepinephrine, which are crucial for attention regulation and impulse control. Due to its potential for misuse, Vyvanse is classified as a Schedule 8 controlled medicine in Australia, ensuring strict regulation and oversight to prevent abuse.

What Color are Vyvanse Capsules in Australia?

Vyvanse capsules in Australia come in various strengths, each identifiable by its distinct color and imprints. The 20mg capsules are blue and orange, while the 30mg variant features a light blue and light orange design. For the 40mg dose, the capsule is pink and orange, and the 50mg strength is represented by a blue and yellow combination. Each capsule also has an identifiable "s489" imprint which aids in distinguishing between different strengths, ensuring the correct dosage is administered.

Do You Have to Pay for ADHD Meds in Australia?

Managing ADHD in Australia involves various costs that greatly impact families and patients. When a Vyvanse prescription is obtained through the PBS, the out-of-pocket expense is significantly reduced. However, patients and families often encounter additional financial responsibilities such as specialist consultation fees required for ADHD diagnosis and ongoing management, which can range widely depending on the professionalism and expertise of the treating physician. Overall, while PBS subsidies help alleviate some financial burdens related to ADHD medication, it is prudent for families to prepare for other associated costs in order to sustainably manage the condition.